Recovery 01' original form ancl function from c1amaged organs 01' tissues is olltmost goal of regenera tive meclicine. Va riolls methods such as moleclll ar biology. drug c1elivery system, biomaterials. tissue engineering have been s tllcliecl and appl iecl in that field . 1'he core factor of all 01' these kinds of efforts might be the cells including stem cells 01' progenitor cell s . AclllJt progenitor 01' stem cells have many advantages for therapeutic meclicine, inclucling free form ethi cal probl em. easiness in collection and clllture. Bone marrow‘ fat tissue, peripheral blood. placenta‘ ancl umbilicaJ cord bloocl a re preferable source 01' acllllt stem cells 01' progenitors. ]-]uman umbilical cord bloocl. taken form vein of corcl after baby c1elivery‘ are known to contain many progenitor cells. Since Boyse et al reportecl bone marrow transplantation with hllman cord blood CD34+ cells f'or leukemia. functional cells in human cord blood have been the cells of great interest. 1n this study‘ the a u thors i s이 ated peripheral bloocl mononuciear celJs. endothelial progenitors‘ late outgrowth vascular endothelial-like cells‘ ancl mesenchymal stem cell- like cells from human umbilical cord blood and a pplied in bony defects, myocardiac infarction and limb ischemic lesl0n Al I of these fllnctional cells showed favorable healing capacity and their effects primarily based on enhanced anglOgenesls Conclllsively. a lthollgb the precise cha racteristics are not well-described‘ the current stucly reveals that various types of functional cell s of human umbilical cord blood have some stem cell or progenitors features and play an important r ole in ti ssue regeneration

Ankylosing spondylitis (AS) is an inflammatory joint disease affecting the axial skeleton, peripheral joints, entheses, and extra-articular site. Non-steroidal anti-inflammatory agents are the first line drugs for treatment of AS. Sulfasalazine is regarded as the second line drug and is usually used on AS patients with concomitant peripheral arthritis. Sulfasalazine has side effects, including liver toxicity, hematological abnormality, skin eruption, and other symptoms. However, eosinophilic pleural effusion is rare. Thus, we report on a patient with peripheral eosinophilia and eosinophilic pleural effusion after taking sulfasalazine for treatment of AS.